Giving voice back.
Without surgery.

Lucen reads intent directly from the brain, from outside the skull. No implant. No operating room.

Think speech.
The problem

Millions have lost the ability to speak. To ALS, to stroke, to injury. Today, their only real option is brain surgery. We think that's the wrong price to ask.

Losing speech means losing connection

Conversation, work, independence. The parts of life most of us never think about become the hardest things in the world.

Implants ask too much

Craniotomy. Hardware in the brain. Long recovery, real risk, and access limited to a handful of surgical centers worldwide.

Non-invasive tech has been too weak, until now

Reading through the skull has historically meant blurry, low-bandwidth signals. Lucen's sensing approach changes that equation entirely.

The technology

Watch a thought
become a word.

01 · SENSE

Read the brain from outside it

A fundamentally new sensing approach captures raw neural activity through the skull. No incision. Nothing implanted. Ever.

02 · DECODE

Turn signal into intent

Our intent-decoding engine translates noise into meaning: not just what you'd say, but what you want to do. It learns you, and sharpens every day.

03 · EXPRESS

Speak, type, act. Instantly

Intent becomes speech, text, and control of the digital world in real time. Communication restored.

Applications

It starts with speech.
It doesn't stop there.

A safe, scalable window into intent isn't one product. It's a platform. Restored communication, accessibility, health, creation, and beyond. At every scale, for every life.

Explore the applications
Built for the world

What implants promised a few,
Lucen is building for everyone.

Because it's non-invasive, Lucen isn't rationed by operating rooms or surgeons. It can be manufactured, shipped, and worn by anyone, anywhere, at any scale.

Lucen icon
"The future of human-computer connection shouldn't require a scalpel. We're building the one that doesn't."

Be first to speak
without saying a word.

Join the Lucen waitlist for early access, research updates, and the moment we open our first trials.

No spam, only meaningful updates.